Full-Time
Physics and Engineering Research Associate
UntilLabs
51-200 employees
Advances reversible organ cryopreservation technology
Compensation Overview
$75k - $150k/yr
Oakland, CA, USA
In Person
 Biology & Biotech (1) |
|---|
- Undergraduate degree or equivalent work experience in a scientific discipline (engineering, physics, biology, etc.)
- Experience with standard lab techniques and equipment
- Demonstrations of exceptional ability and autonomy in past work
- Engage in full stack engineering with a high degree of autonomy and breadth of skill across electrical, mechanical, and materials design, with strong emphasis on first principles thinking
- Contribute to projects involving development of perfusion systems, cryoprotectant formulations, and vitrification and rewarming hardware as part of an interdisciplinary team
UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2024
Simplify's Take
What believers are saying
- Raised $58M Series A in September 2025 from Founders Fund, Lux Capital, Field Ventures.
- Enables organ banking, better matching, reduces waitlist deaths from time constraints.
- Foundational for whole-body preservation, backed by over $100M funding.
What critics are saying
- FDA lacks approval framework, delaying commercialization 3-5 years.
- Normothermic systems from OrganOx, Transmedics capture market pre-approval.
- Cryoprotectant toxicity triggers rejection, forces redesign in 24-36 months.
What makes UntilLabs unique
- Until Labs develops reversible cryopreservation for organs using vitrification without ice formation.
- Engineers five dimensions: perfusion, cryoprotectants, cooling, rewarming, and post-thaw assays.
- Progressed from neural slices to preclinical kidneys, hearts, lungs, livers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Commuter Benefits
Professional Development Budget
Company News
Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.
Fenwick represents Until Labs in $58M Series A funding.